Aprobación de biosimilares de ustekinumab: ¿un cambio en la primera línea del tratamiento biológico de la psoriasis?

• Sofia Gómez-Martínez ^[1] ; Daniel Morgado-Carrasco ^[1]
  1. [1] Hospital Clinic Barcelona

     Hospital Clinic Barcelona

     Barcelona, España

     
• Localización: Piel: Formación continua en dermatología, ISSN 0213-9251, Vol. 39, Nº. 6 (Junio-Julio), 2024, págs. 315-316
• Idioma: español
• DOI: 10.1016/j.piel.2024.03.006
• Títulos paralelos:
  • Approval of ustekinumab biosimilars: First-line biological treatment for psoriasis set to change?
• Enlaces
  • Texto Completo Ejemplar
• Referencias bibliográficas
  • Stelara: Summary of Product Characteristics. Published online January 23, 2009. [consultado 14 Ene 2024]. Disponible en: https://www.ema.europa.eu/en/documents/productinformation/stelara-epar-product-information_en.pdf.
  • Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years...
  • Gerdes S, Hoffmann M, Asadullah K, et al. Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with...
  • Yiu ZZN, Becher G, Kirby B, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab,...
  • Ye L, Wu Z, Li C, et al. Off-label uses of ustekinumab. Dermatol Ther. 2022;35(12):e15910. https://doi.org/10.1111/dth.15910.